Group 1 - Company Jizhi Technology has signed an agreement to acquire a 3.00% stake in Xiamen Yunchuang Xingchen Venture Capital Partnership for 15.75 million yuan, investing in an AI model company [1] - Longpan Technology expects a procurement transaction with Ningde Times not to exceed 7 billion yuan in 2026 [2] - Zhanzi Island has provided a loan of 14.5087 million yuan to its associate company, which has failed to repay on time, leading to a planned special audit [3] Group 2 - CICC is actively progressing the merger with Dongxing Securities and Xinda Securities, with related audit work still ongoing [4] - Jintong Co. plans to acquire a 24% stake in Anhui Jinsan Molybdenum Co. from Zijin Mining for 1.731 billion yuan, aiming to strengthen resource security [5] - SF Holding has entered a strategic cooperation with Jitu Express, with mutual shareholding arrangements to enhance operational synergies [6][7] Group 3 - Zhizhi New Materials' stock will resume trading on January 16, 2026, after a six-day trading suspension due to price volatility, clarifying that its business does not involve AI applications [8][9] - ST Chengchang's stock will also resume trading on January 16, 2026, after completing a review of trading anomalies [10] - Jiangxi Copper's subsidiary has signed an investment option agreement with First Quantum, planning to invest 6.5 million USD for a 14.9% stake in Lakeside [11] Group 4 - Aerospace Intelligence forecasts a net profit of 792 million to 910 million yuan for 2025, indicating a growth of 0.00% to 15.00% year-on-year [12] - SAIC Group expects a net profit of 9 billion to 11 billion yuan for 2025, representing a year-on-year increase of 438% to 558% [13] - Chongqing Steel anticipates a net loss of 2.5 billion to 2.8 billion yuan for 2025, showing an improvement from a previous loss of 3.196 billion yuan [14] Group 5 - Tongxing Technology projects a net profit of 68 million to 88 million yuan for 2025, reflecting a year-on-year increase of 74.2% to 125.44% [15] - Power New Science expects a net profit of 2.752 billion to 2.852 billion yuan for 2025, marking a turnaround from previous losses [16] - Sanmei Co. anticipates a net profit of 1.99 billion to 2.15 billion yuan for 2025, with a year-on-year growth of 155.66% to 176.11% [17] Group 6 - Luoyang Molybdenum expects a net profit of 20 billion to 20.8 billion yuan for 2025, indicating a year-on-year increase of 48% to 54% [18] - New Nuo Wei forecasts a net loss of 170 million to 255 million yuan for 2025, a shift from a profit of 53.726 million yuan in the previous year [19] - Aerospace Information anticipates a net loss of 700 million to 980 million yuan for 2025, indicating a transition to losses [20] Group 7 - Aidi Te plans to reduce its shareholding by up to 3.00% through various trading methods due to funding needs [21]

Group 1: Stock Performance and Trading Updates - Liou Co., Ltd. announced a stock suspension for verification due to a 96.77% deviation in closing price over 10 consecutive trading days from December 31, 2025, to January 15, 2026, with a suspension expected to last no more than 3 trading days [1] - Aerospace Development's major shareholder reduced holdings by 12.26 million shares during a period of stock trading volatility, planning further reductions in the future [3] - Zhite New Materials' stock will resume trading on January 16, 2026, after a 198.57% increase over six consecutive trading days, confirming that its business does not involve AI applications [5] Group 2: Financial Performance Forecasts - SAIC Motor Corporation expects a net profit of 9 billion to 11 billion yuan for 2025, representing a year-on-year increase of 438% to 558%, with wholesale vehicle sales projected at 4.5075 million units, up 12.32% from the previous year [1] - Kunlun Wanwei anticipates a net loss for 2025, indicating a downturn in operational performance [2] - Luoyang Molybdenum Co. forecasts a net profit of 20 billion to 20.8 billion yuan for 2025, reflecting a year-on-year increase of 48% to 54% due to rising product prices and effective cost control [3] - Tianji Co. expects a net profit of 70 million to 105 million yuan for 2025, recovering from a loss of 1.361 billion yuan in the previous year, driven by increased demand in the new energy and energy storage markets [7] Group 3: Strategic Partnerships and Investments - Longpan Technology signed a procurement agreement with CATL, expecting transactions not to exceed 7 billion yuan in 2026 to support its new energy business [4] - Jizhi Technology acquired a 3% partnership stake in an investment fund focused on AI large model companies, investing 15.75 million yuan [6] - Aerospace Information anticipates a net loss of 700 million to 980 million yuan for 2025, indicating a significant operational challenge [13]

Group 1 - Huasheng Tiancheng's AI-related revenue currently accounts for a low proportion of overall revenue, indicating that it does not significantly impact the company's performance [2] - CICC's merger with Dongxing Securities and Xinda Securities is still undergoing audit work, which has not yet been completed [2] - Xinhua Department Store confirmed that there are no undisclosed major matters related to semiconductor asset injections, addressing market rumors [3] Group 2 - Zhong Rare Metals signed a strategic cooperation agreement with Xian Dao Group to enhance market share and industry influence in rare metals [4] - Zhongtian Rocket reported losses in its carbon/carbon thermal field materials business due to intensified competition in the photovoltaic industry [5] - Zhongyuan Nepe proposed to acquire 59% of Zhongyuan Jikean's equity for 143 million yuan, which will make it a wholly-owned subsidiary [5] Group 3 - Jiangxi Copper's subsidiary signed a cooperation agreement with First Quantum Minerals for exploration projects [6] - China Nuclear Power's Jiangsu Xuwei Nuclear Energy Heating Power Plant's first unit is set to pour its first concrete on January 16, 2026 [6] - ST Aowei's stock may be delisted if it continues to trade below par value [6] Group 4 - Triangle Tire plans to invest 3.219 billion yuan in a new high-performance tire project in Cambodia, expected to generate annual revenue of 2.585 billion yuan [7] - Baoxin Technology intends to publicly sell part of its subsidiary's assets, with a valuation of 50.2334 million yuan [7] - Nong Shang Environment's computing infrastructure project has not progressed as planned due to funding issues [8] Group 5 - Golden Dragon Fish plans to transfer stakes in two subsidiaries to Mars China for a total of 60 million USD, which is expected to impact its 2026 earnings significantly [8] - Jin Dao Technology intends to issue convertible bonds to raise up to 306 million yuan for various projects [8] - Aerospace Information expects a net loss of 700 million to 980 million yuan for 2025 due to industry changes [10] Group 6 - Tianji Co. forecasts a net profit of 70 million to 105 million yuan for 2025, recovering from a previous loss [10] - Muyuan Foods anticipates a net profit decrease of 12.2% to 17.79% for 2025 [11] - SAIC Group expects a net profit increase of 438% to 558% for 2025, driven by sales growth [12] Group 7 - Haolaike expects a significant drop in net profit for 2025, projecting a decrease of 75.16% to 83.23% [13] - Hainan Development anticipates a net loss of 440 million to 565 million yuan for 2025 [13] - Shuangliang Energy expects to report a loss for 2025 [14] Group 8 - Aijian Group also anticipates a loss for 2025 [14] - Meijin Energy forecasts a net loss of 850 million to 1.25 billion yuan for 2025 [14] - Kunlun Wanwei expects to report a loss for 2025 [14] Group 9 - Xue Rong Biological expects a net profit of 29 million to 40 million yuan for 2025, recovering from a previous loss [15] - Xin Nuo Wei anticipates a net loss of 170 million to 255 million yuan for 2025 due to increased R&D expenses [15] - Shengnuo Biological expects a net profit increase of 204.42% to 280.53% for 2025 [16] Group 10 - Longyuan Construction forecasts a net loss of 1 billion to 1.5 billion yuan for 2025 [17] - Kosen Technology expects a net loss of 245 million to 330 million yuan for 2025 [17] - Daqian Ecology anticipates a net loss of 100 million to 120 million yuan for 2025 [17] Group 11 - Lianfa Co. expects a net profit increase of 38.92% to 58.77% for 2025 [18] - Chongqing Steel anticipates a net loss of 2.5 billion to 2.8 billion yuan for 2025, but expects to reduce losses compared to the previous year [18] - Tongxing Technology forecasts a net profit increase of 74.2% to 125.44% for 2025 [19] Group 12 - Siyuan Electric expects a net profit of 3.163 billion yuan for 2025, a 54.35% increase year-on-year [19] - Luoyang Molybdenum expects a net profit increase of 47.8% to 53.71% for 2025 [20] - Nawei Technology anticipates a net profit increase of 54.51% to 75.03% for 2025 [20] Group 13 - Jingjia Micro expects a net loss of 120 million to 180 million yuan for 2025 [21] - Southwest Securities forecasts a net profit increase of 47% to 57% for 2025 [22] - Wankai New Materials expects a net profit of 156 million to 203 million yuan for 2025, recovering from a previous loss [22] Group 14 - Yilian Network anticipates a slight decrease in net profit for 2025, projecting a decline of 0% to 4% [23] - Baofeng Energy expects a net profit increase of 73.57% to 89.34% for 2025 [23] - Sanmei Co. forecasts a net profit increase of 155.66% to 176.11% for 2025 [23] Group 15 - Zhenyu Technology expects a net profit increase of 96.89% to 116.58% for 2025 [24] - Fute Technology anticipates a net profit increase of 121.98% to 164.26% for 2025 [24] - Guoli Electronics expects a net profit increase of 124.89% to 164.57% for 2025 [24] Group 16 - Shenyu Co. expects a slight decrease in net profit for 2025, projecting a decline of 0.05% to 11.37% [25] - Rongchang Biological plans to increase its share repurchase price limit to 116 yuan per share [26] - Defu Technology plans to repurchase shares for 75 million to 150 million yuan [26] Group 17 - ST Chengchang's stock will resume trading on January 16 after completing a trading fluctuation investigation [27] - Zhi Te New Materials will also resume trading on January 16 after confirming no major changes in business operations [27] - Lio Co. will suspend trading starting January 16 for stock fluctuation investigation [27]

Core Viewpoint - The company Xinnuo Wei (300765) has announced that by December 31, 2025, it expects to have a total of 20,677 shareholders across its consolidated ordinary accounts and margin trading credit accounts [1] Group 1 - The company is actively engaging with investors through interactive platforms [1] - The projected number of shareholders indicates potential growth in investor interest and participation [1]

Core Viewpoint - XinNuoWei (300765) is expected to report a net profit attributable to shareholders of between -170 million to -255 million yuan for the year 2025, indicating a shift from profit to loss year-on-year [1] Group 1: Financial Performance - The company anticipates a significant decline in profitability for 2025, with a projected net loss compared to previous earnings [1] - The expected net loss range for 2025 is between -170 million to -255 million yuan [1] Group 2: Business Operations - In early November 2025, the company completed the acquisition of an additional 29% minority stake in its subsidiary, JuShi Bio, increasing its ownership to 80% [1] - JuShi Bio is currently not profitable due to substantial investments in its research pipeline, which will further impact the company's consolidated financial statements as the ownership stake increases [1]

Core Viewpoint - The company Xinnowei (300765) has announced a significant expected loss for the fiscal year 2025, indicating a substantial decline in profitability compared to the previous year [1] Financial Performance - The company anticipates a net loss attributable to shareholders of between 170 million to 255 million yuan for 2025, representing a decrease of 416% to 575% year-over-year [1] - The net profit, excluding non-recurring gains and losses, is expected to be a loss of 210 million to 315 million yuan, reflecting a decline of 596% to 844% compared to the same period last year [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 石藥創新製藥股份有限公司 截至2025年12月31日止年度之業績預告 按深圳證券交易所之相關規定，石藥集團有限公司（「本公司」）之附屬公司石藥創新製藥股份 有限公司（「石藥創新」，其股份於深圳證券交易所創業板市場上市（ 股票代碼：300765）），已 於2026年1月15日發佈其截至2025年12月31日止年度之業績預告公告（「業績預告公告」）於深 圳證券交易所網站資訊披露頁面http:// www.szse.cn/ disclosure/listed/ notice/index.html。 本公司及董事會全體成員保證信息披露的內容真實、準確、完整，沒有虛假記載、誤導 性陳述或重大遺漏。 本公告附錄（「附錄」）所載由石藥創新根據中國企業會計準則編製之業 ...

【品大事】 激智科技：受让1575万元投资基金份额并投资于AI大模型公司 激智科技公告，与弘信创业工场投资集团股份有限公司签订财产份额转让协议，受让其持有的厦门云创星宸创业投资合伙企业（有限合伙）1575万元财产份 额，成为其有限合伙人之一，持有其3.00%的合伙份额。本次投资为自有资金，不构成关联交易或重大资产重组。 龙蟠科技：预计2026年宁德时代将与公司发生不超过70亿元的采购交易 龙蟠科技公告，公司与宁德时代签署了《持续关连交易协议（采购）》。协议约定，2026会计年度，宁德时代（含其附属公司及其参股30%以上公司）向公 司及公司附属公司支付的交易金额上限将不得超过公司根据《香港联合交易所有限公司证券上市规则》于香港联合交易所有限公司网站不时披露的金额。公 司预计2026年，宁德时代将与公司发生不超过70亿元的采购交易。 獐子岛：参股公司普冷獐子岛借款逾期 獐子岛公告，公司于2024年向参股公司普冷獐子岛提供1450.87万元借款，年利率6.08%，但普冷獐子岛未能按期偿还本金及罚息。该笔借款用途为生产经 营，普冷獐子岛为獐子岛关联法人。公司已发催款函，并计划进行专项审计以评估其偿债能力。此事项不会影 ...

Core Viewpoint - XinNuoWei (300765) expects a net profit loss of 170 million to 255 million yuan for 2025, compared to a net profit of 53.7263 million yuan in the same period last year [1] Group 1: Financial Performance - The company anticipates a significant decline in net profit for 2025, projecting a loss between 170 million and 255 million yuan [1] - In the previous year, the company reported a net profit of 53.7263 million yuan [1] Group 2: Research and Development Investment - To accelerate the advancement of its innovative pipeline, the company has increased its R&D expenditure to approximately 1 billion yuan for the year, marking a substantial year-on-year increase [1] - The rise in R&D expenses is identified as a key factor impacting the current profit situation [1]

Core Viewpoint - The company, XinNuoWei (300765.SZ), forecasts a net loss attributable to shareholders of 170 million to 255 million yuan for the year 2025, marking a shift from profit to loss year-on-year [1] Group 1: Financial Performance - The company anticipates a significant increase in R&D expenses, projected to reach approximately 1 billion yuan, which is a substantial year-on-year growth and a key factor affecting current profits [1] - The acquisition of an additional 29% minority stake in its subsidiary, Jushi Biotechnology, has increased the company's ownership to 80%, which will amplify the impact of Jushi's losses on the consolidated financial statements [1] Group 2: R&D Progress - During the reporting period, the company made significant advancements in its innovation pipeline, with four antibody drugs, six ADC products, and one mRNA vaccine receiving clinical trial approvals for the first time in 2025 [1] - A monoclonal antibody product, Omabuzumab for new indications, has been approved for market launch, while another monoclonal antibody product, Pertuzumab injection, has had its market application accepted [1] - Two ADC products have entered the Phase III clinical stage, reflecting the company's commitment to advancing its research and development efforts [1] Group 3: Functional Raw Materials Business - The company has worked to strengthen its position in the functional raw materials sector, particularly by increasing sales of caffeine products [1] - However, due to market factors, the gross margin and profitability of caffeine products have slightly declined compared to the same period last year, leading to a decrease in profits from the functional raw materials business [1]